HK Stock Market Move | IMMUNEONCO-B (01541) up more than 7%, announces positive progress with IMM2510 in the treatment of IO treated advanced lung squamous cell carcinoma.

IMMUNEONCO-B(01541) rose more than 7%, as of press time, up 7.36% to HK$3.21, with a turnover of HK$26.7097 million. On the news front, on June 1st, Immuneonc announced that its self-developed dual-target drug VEGFPD-L1, Pereirafoalpha (IMM2510), officially released its Phase I clinical trial data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting (abstract number: 8580). The data showed that IMM2510 not only had significant efficacy in advanced lung squamous cell carcinoma patients who had progressed after immunotherapy (IO), but also demonstrated excellent safety characteristics distinct from similar products. The company stated that based on the positive data and exposure-effect analysis results from the Phase I study, a recommended dose of 20mg/kg Q2W for Phase II (RP2D) has been established, and plans for Phase III clinical trials are underway.